Processa Pharmaceuticals, Inc. (PCSA) Form 10-Q — Aug 14, 2026
Processa Pharmaceuticals reported a Q2 2026 net loss of $3.27 million ($1.19 per share), with six-month losses of $6.64 million ($2.47 per share), and held just $196,325 in cash at June 30, 2026 against a stockholders' deficit of $317,341 and an accumulated deficit of $107.4 million. Net cash used in operations was $5.6 million in the first half. The dominant event is the July 28, 2026 acquisition of Vidya Therapeutics, which brings lead asset VT-7208, an orally available CNS-penetrant BTK inhibitor targeting food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.
Key figures
- Total Assets
- 2069562
- Cash Position
- 196325
- Shares Outstanding
- 2793386
- Chz coins sold
- 11000000
- Chz sale proceeds
- 186000
- Chiliz group stake
- 10.9% of common stock outstanding at June 30, 2026
- Ga expense q2 2026
- 1686261
- Rd expense q2 2025
- 2447286
- Rd expense q2 2026
- 649877
- Preferred shares sold
- 163,774.679 Series A Preferred (163,774,679 common as-converted)
- Elion settlement payment
- 650000
- Preferred price per share
- $1,221.19 per preferred share ($1.22119 as-converted)
- Digital assets chz fair value
- 472003
- Private placement net proceeds
- 183300000
- Private placement gross proceeds
- 200000000
- Vidya holder ownership post deal
- approximately 46.0% (fully diluted)
- Legacy holder ownership post deal
- approximately 1.0% (fully diluted)
- Placement investor ownership post deal
- approximately 53.0% (fully diluted)
- Post conversion new investor ownership
- approximately 99.0%
- Shares issuable on preferred conversion
- 307063330
Price after filing
Close on the filing date to close N calendar days later (from $2.43). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.